<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" >

<channel><title><![CDATA[BIO BENCH - YOUR RELIABLE CRO PARTNER! - BioNews]]></title><link><![CDATA[https://www.bio-bench.com/bionews]]></link><description><![CDATA[BioNews]]></description><pubDate>Sat, 31 Jan 2026 00:14:13 +0800</pubDate><generator>Weebly</generator><item><title><![CDATA[What's new - Week 13 2025 (24/Mar - 30/Mar)]]></title><link><![CDATA[https://www.bio-bench.com/bionews/april-03rd-2025]]></link><comments><![CDATA[https://www.bio-bench.com/bionews/april-03rd-2025#comments]]></comments><pubDate>Thu, 03 Apr 2025 08:53:26 GMT</pubDate><category><![CDATA[Uncategorized]]></category><guid isPermaLink="false">https://www.bio-bench.com/bionews/april-03rd-2025</guid><description><![CDATA[Organic molecules of unprecedented size discovered on MarsFull ArticleScientists detected the longest organic molecules identified to date on Mars, containing up to 12 consecutive carbon atoms, which could exhibit features similar to fatty acids produced on Earth by biological activity.Dravet Gene Therapy Tested in Mice, Sarepta’s Setback, and AstraZeneca UpdatesFull ArticleResearchers discussed a potential gene replacement therapy for Dravet Syndrome tested in mice with promising results, alo [...] ]]></description><content:encoded><![CDATA[<div><div id="886963106107044447" align="center" style="width: 100%; overflow-y: hidden;" class="wcustomhtml"><div align="center" style='margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:115%;font-size:16px;font-family:"Calibri",sans-serif;'><table style="border-collapse: collapse;border: none;width: 803px;"><tbody><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:justify;'><strong><span style='font-size:19px;font-family:"Arial",sans-serif;color:black;'>Organic molecules of unprecedented size discovered on Mars</span></strong></p></td><td rowspan="2" style="width:88.6pt;border:solid windowtext 1.0pt;border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:center;'><a href="https://www.sciencedaily.com/releases/2025/03/250324152436.htm"><strong><span style='font-family:"Arial",sans-serif;'>Full Article</span></strong></a></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:63.55pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:justify;'><span style='font-family:"Arial",sans-serif;color:black;'>Scientists detected the longest organic molecules identified to date on Mars, containing up to 12 consecutive carbon atoms, which could exhibit features similar to fatty acids produced on Earth by biological activity.</span></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:justify;'><strong><span style='font-size:19px;font-family:"Arial",sans-serif;color:black;'>Dravet Gene Therapy Tested in Mice, Sarepta&rsquo;s Setback, and AstraZeneca Updates</span></strong></p></td><td rowspan="2" style="width:88.6pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:center;'><a href="https://www.genengnews.com/topics/genome-editing/dravet-gene-therapy-tested-in-mice-sareptas-setback-and-astrazeneca-updates/"><strong><span style='font-family:"Arial",sans-serif;'>Full Article</span></strong></a></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:63.55pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:justify;'><span style='font-family:"Arial",sans-serif;color:black;'>Researchers discussed a potential gene replacement therapy for Dravet Syndrome tested in mice with promising results, alongside updates on Sarepta&rsquo;s clinical trials and AstraZeneca&rsquo;s recent activities.</span></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><strong><span style='font-size:19px;font-family:"Arial",sans-serif;color:black;'>Researchers see breakthrough in efficient biofuel production</span></strong></p></td><td rowspan="2" style="width:88.6pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:center;'><a href="https://www.biofuelsdigest.com/bdigest/researchers-see-breakthrough-in-efficient-biofuel-production/"><strong><span style='font-family:"Arial",sans-serif;'>Full Article</span></strong></a></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:63.55pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><span style='font-family:"Arial",sans-serif;color:black;'>A collaboration between the University of Cincinnati and Oak Ridge National Laboratory reported significant improvements in biofuel production efficiency.</span></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><strong><span style='font-size:19px;font-family:"Arial",sans-serif;color:black;'>Enhertu Successor Gets First FDA OK in Breast Cancer</span></strong></p></td><td rowspan="2" style="width:88.6pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:center;'><a href="https://www.biopharmadive.com/news/astrazeneca-daiichi-enhertu-successor-first-fda-ok-breast-cancer/"><strong><span style='font-family:"Arial",sans-serif;'>Full Article</span></strong></a></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:63.55pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><span style='font-family:"Arial",sans-serif;color:black;'>The FDA approved a new breast cancer treatment, marking a significant advancement in oncology therapeutics.</span></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><strong><span style='font-size:19px;font-family:"Arial",sans-serif;color:black;'>YolTech Therapeutics Begins First Trial of In Vivo CRISPR Therapy for Blood Disease</span></strong></p></td><td rowspan="2" style="width:88.6pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:center;'><a href="https://endpts.com/chinese-startup-begins-first-trial-of-in-vivo-crispr-therapy-for-blood-disease/"><strong><span style='font-family:"Arial",sans-serif;'>Full Article</span></strong></a></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:63.55pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><span style='font-family:"Arial",sans-serif;color:black;'>YolTech Therapeutics initiated the first clinical trial using in vivo CRISPR gene-editing therapy to treat a blood disorder.</span></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><strong><span style='font-size:19px;font-family:"Arial",sans-serif;color:black;'>Microbiome May Open Next Chapter in Transplant Diagnostics</span></strong></p></td><td rowspan="2" style="width:88.6pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:center;'><a href="https://www.genomeweb.com/microbiome-may-open-next-chapter-in-transplant-diagnostics/"><strong><span style='font-family:"Arial",sans-serif;'>Full Article</span></strong></a></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:63.55pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><span style='font-family:"Arial",sans-serif;color:black;'>Emerging preclinical data suggest that microbiome analysis could play a crucial role in improving diagnostics for organ transplant outcomes.</span></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><strong><span style='font-size:19px;font-family:"Arial",sans-serif;color:black;'>JP Morgan Healthcare Conference Highlights: Oxford Nanopore, 10x Genomics, Bruker, Qiagen</span></strong></p></td><td rowspan="2" style="width:88.6pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:center;'><a href="https://www.genomeweb.com/jp-morgan-healthcare-conference-highlights-oxford-nanopore-10x-genomics-bruker-qiagen/"><strong><span style='font-family:"Arial",sans-serif;'>Full Article</span></strong></a></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:63.55pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><span style='font-family:"Arial",sans-serif;color:black;'>Key developments from the JP Morgan Healthcare Conference included product launch plans from companies like Oxford Nanopore and Qiagen.</span></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><strong><span style='font-size:19px;font-family:"Arial",sans-serif;color:black;'>GRI Bio&rsquo;s Tazarotene Shows Phase IIa Promise in Idiopathic Pulmonary Fibrosis</span></strong></p></td><td rowspan="2" style="width:88.6pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:center;'><a href="https://www.bioworld.com/gribio-tazarotene-shows-phase-IIa-promise-in-idiopathic-pulmonary-fibrosis/"><strong><span style='font-family:"Arial",sans-serif;'>Full Article</span></strong></a></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:63.55pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><span style='font-family:"Arial",sans-serif;color:black;'>GRI Bio Inc.&rsquo;s oral tazarotene demonstrated promising interim safety results in a Phase IIa trial for treating idiopathic pulmonary fibrosis.</span></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><strong><span style='font-size:19px;font-family:"Arial",sans-serif;color:black;'>Abbott&rsquo;s Triclip Shows Benefit in Tricuspid Valve Repair Study</span></strong></p></td><td rowspan="2" style="width:88.6pt;border-top:none;border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt;height:34.7pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;text-align:center;'><a href="https://www.bioworld.com/abbott-triclip-shows-benefit-in-tricuspid-valve-repair-study/"><strong><span style='font-family:"Arial",sans-serif;'>Full Article</span></strong></a></p></td></tr><tr><td style="width:513.85pt;border:solid windowtext 1.0pt;border-top: none;padding:0cm 5.4pt 0cm 5.4pt;height:63.55pt;"><p style='margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;line-height:normal;font-size:16px;font-family:"Calibri",sans-serif;'><span style='font-family:"Arial",sans-serif;color:black;'>Two-year results from the TRILUMINATE trial indicated that Abbott Laboratories&rsquo; Triclip device effectively reduces hospitalizations for patients undergoing tricuspid valve repair.</span></p></td></tr></tbody></table></div></div></div>]]></content:encoded></item></channel></rss>